^
No biomarker
Hairy Cell Leukemia
cladribine
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
moxetumomab pasudotox
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
vemurafenib + rituximab
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
pentostatin
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
rituximab/hyaluronidase
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
rituximab
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
vemurafenib
Sensitive: A2 - Guideline
No biomarker
Hairy Cell Leukemia
ibrutinib
Sensitive: A2 - Guideline
BRAF V600E
Hairy Cell Leukemia
dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Hairy Cell Leukemia
dabrafenib + rituximab
Sensitive: C3 – Early Trials
TP53 mutation
Hairy Cell Leukemia
rituximab + cladribine
Resistant: C3 – Early Trials
MYD88 L265P + BRAF V600E
Hairy Cell Leukemia
rituximab
Sensitive: C4 – Case Studies
KRAS mutation
Hairy Cell Leukemia
vemurafenib
Resistant: C4 – Case Studies